Alexandria Hammond
Stock Analyst at B of A Securities
(2.09)
# 2,755
Out of 4,784 analysts
14
Total ratings
50%
Success rate
-3.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Upgrades: Buy | $35 → $63 | $43.58 | +44.56% | 2 | Jan 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $635.83 | +80.87% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $25.01 | -0.04% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $32.12 | +24.53% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $87.60 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $821.67 | +21.70% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $163.13 | +16.47% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $111.16 | -1.04% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $58.90 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $140.33 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $202.72 | +1.12% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $337.27 | -55.53% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $8.96 | +234.82% | 1 | Apr 22, 2024 |
Akero Therapeutics
Jan 30, 2025
Upgrades: Buy
Price Target: $35 → $63
Current: $43.58
Upside: +44.56%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $635.83
Upside: +80.87%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.01
Upside: -0.04%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $32.12
Upside: +24.53%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $87.60
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $821.67
Upside: +21.70%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $163.13
Upside: +16.47%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $111.16
Upside: -1.04%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $58.90
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $140.33
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $202.72
Upside: +1.12%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $337.27
Upside: -55.53%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $8.96
Upside: +234.82%